These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 7881698)

  • 1. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.
    Bryson HM; Sorkin EM
    Drugs; 1994 Dec; 48(6):894-906. PubMed ID: 7533697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dornase alfa: a new option in the management of cystic fibrosis.
    Witt DM; Anderson L
    Pharmacotherapy; 1996; 16(1):40-8. PubMed ID: 8700791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
    Shak S
    Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dornase alfa for cystic fibrosis.
    Yang C; Chilvers M; Montgomery M; Nolan SJ
    Cochrane Database Syst Rev; 2016 Apr; 4():CD001127. PubMed ID: 27043279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
    Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
    N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dornase alfa for cystic fibrosis.
    Yang C; Montgomery M
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD001127. PubMed ID: 33735508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dornase alfa for cystic fibrosis.
    Yang C; Montgomery M
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001127. PubMed ID: 30187450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
    Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
    Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The overuse or underuse of dornase alfa.
    Shah PL; Hodson ME
    Curr Opin Pulm Med; 1997 Nov; 3(6):410-3. PubMed ID: 9391759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of dornase alfa in the treatment of cystic fibrosis.
    Cramer GW; Bosso JA
    Ann Pharmacother; 1996 Jun; 30(6):656-61. PubMed ID: 8792953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
    Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
    Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
    Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
    Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dornase alfa for cystic fibrosis.
    Jones AP; Wallis C
    Cochrane Database Syst Rev; 2010 Mar; (3):CD001127. PubMed ID: 20238314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled mannitol for cystic fibrosis.
    Nevitt SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2020 May; 5(5):CD008649. PubMed ID: 32358807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled mannitol for cystic fibrosis.
    Nevitt SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD008649. PubMed ID: 29424930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled mannitol for cystic fibrosis.
    Nolan SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008649. PubMed ID: 26451533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.